The Denvax is dendritic cell-based cancer immunotherapy for solid cancers in various stages of the disease. It is an autologous treatment, which involves the patient's own mononuclear cells transformed into cancer-specific dendritic cells. Designed to be specific, Denvax targets only the cancer cells without harming the healthy ones. It is safe and effective and works best to prevent relapse and recurrences, the major cause of mortality and morbidity. Denvax helps in correcting the failed immune surveillance and teaches the immune system to recognize and kill cancer cells.